Treatment of Metformin on women with polycystic ovary syndrome

• 作 者: 曹晓航 张俊吉 施璧 Rolando Martins 罗新
• 机 构: Department of Obstetrics & Gynecology,The First Affiliated Hospital of Jinan University(guangzhou),D
• 出 处: 生殖医学杂志
• 发表日期: 2009年S2期
• 关键词: ovary women cardiovascular regularization endocrine pathogenesis possibly alone

Polycystic ovary syndrome(PCOS) appears to be the most common endocrine disorders of women. It is associated with significant reproductive,endocrine,metabolic,and cardiovascular morbidity.Hyperinsuline-mia and insulin resistance,which result in hyperandrogenemia have been documented as a central role in the pathogenesis of PCOS.Treatment with insulin sensitizer,metformin,has been shown to follow by regularization of menstrual cycle,improved response to ovulation induction and reduction of hyperandrogenism.It possibly prevents early trimester pregnancy loss and decrease the risk of developing typeⅡdiabetes and cardiovascular disease.This article aims to review the current evidence on the use of metformin in women with PCOS.

Polycystic ovary syndrome (PCOS) appears to be the most common endocrine disorders of women. It is associated with significant reproductive, endocrine, metabolic, and cardiovascular morbidity. Hyperinsuline-mia and insulin resistance, which results in hyperandrogenemia have been documented as a central role in the pathogenesis of PCOS. Treatment with insulin sensitizer, metformin, has been shown to follow by regularization of menstrual cycle, improved response to ovulation induction and reduction of hyperandrogenism. It may prevent early trimester pregnancy loss and decrease the risk of developing type II diabetes and cardiovascular disease.This article aims to review the current evidence on the use of metformin in women with PCOS.